Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) just unveiled an update.
JCR Pharmaceuticals Co., Ltd. announced the completion of payment procedures for the disposition of treasury stock as restricted stock compensation. This move, involving 111,000 shares of common stock at 518 yen per share, is part of a strategic initiative to align the interests of directors, executive officers, and employees with the company’s long-term goals, potentially enhancing its operational effectiveness and market position.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company based in Japan, focusing on developing treatments for rare diseases and complex healthcare challenges. With a 50-year legacy, JCR is expanding its presence in the U.S., Europe, and Latin America, offering therapies for conditions like growth disorders, MPS II, and renal anemia, while also advancing investigational products for other rare diseases.
Average Trading Volume: 1,658,996
Technical Sentiment Signal: Hold
Current Market Cap: Yen84.52B
For an in-depth examination of 4552 stock, go to TipRanks’ Overview page.